SCM
NVAX icon

Shelton Capital Management’s Novavax NVAX Stock Holding History

Shelton Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,100
Closed -$228K – 879
2021
Q3 		$228K Buy
+1,100
New +$242K 0.01% 698
2020
Q4 		– Sell
-2,000
Closed -$217K – 790
2020
Q3 		$217K Buy
+2,000
New +$244K 0.01% 658

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Shelton Capital Management's NVAX Position: Q4 2021 in Review

Shelton Capital Management sold out of Novavax (NVAX) in Q4 2021, closing a stake of 1,100 shares — an estimated $228K sold.

Shelton Capital Management first reported a position in NVAX in Q3 2020 and held it in 2 quarters. The position peaked at $228K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • Shelton Capital Management reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • Shelton Capital Management sold 1,100 Novavax shares in Q4 2021, an estimated $228K.
  • Shelton Capital Management first reported a position in Novavax in Q3 2020 and held it in 2 quarters.
  • Shelton Capital Management's Novavax position peaked at $228K in Q3 2021.
  • 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Shelton Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.